Please login to the form below
Erleada
This page shows the latest Erleada news and features for those working in and with pharma, biotech and healthcare.
Janssen’s Erleada combination accepted in Scotland for prostate cancer
The combination therapy significantly improved progression-free and overall survival rates. Janssen – a pharmaceutical arm of Johnson &Johnson – has announced that Erleada (apalutamide), in combination with androgen deprivation therapy (ADT),
Latest news
-
Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer
activity may derive ‘clinical benefit’ from the Erleada/Zytiga combination treatment, according to Janssen. ... In the EU, Erleada is approved for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic
-
Janssen’s Erleada improves survival in certain advanced prostate cancer patients
The TITAN study evaluated Erleada (apalutamide) plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared to placebo plus ADT. ... In the EU, Erleada is approved for the treatment of metastatic castration-sensitive prostate
-
Bayer gets EU nod for prostate cancer drug Nubeqa
J&J's Erleada also demonstrated a reduction in risk of death, cutting the risk by 33% when added to ADT, compared to treatment with placebo and ADT. ... After two years’ follow-up 84% of patients treated with Erleada and ADT were still alive compared
-
Givlaari, Rybelsus lead crowded CHMP recommendations
Nubeqa will go head-to-head in the non-metastatic castration-resistant prostate cancer market with J&J’s Erleada (apalutamide), as well as Pfizer/Astellas’ Xtandi (enzalutamide).
-
J&J gets EMA nod for wider use of Erleada in prostate cancer
Maintains a regulatory lead over rival Xtandi. Johnson &Johnson has clinched another approval for its prostate cancer drug Erleada in Europe, maintaining a regulatory lead over rival Xtandi from Astellas and ... Pfizer. The EMA clearance for Erleada
More from news
Approximately 7 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
Erleada (apalutamide) is the first drug to be cleared on the strength of metastasis-free survival (MFS), a trial endpoint not used before in any FDA cancer drug approval. ... The median MFS for patients taking Erleada was 40.5 months compared to 16.2
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
